HIV/AIDS - Research and Palliative Care
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings
(4821) Total Article Views
Authors: Lee JSF, Calmy A, Andrieux-Meyer I, Ford N
Published Date January 2012
Volume 2012:4 Pages 5 - 15
|Received:||17 October 2011|
|Accepted:||28 November 2011|
|Published:||12 January 2012|
1Médecins Sans Frontières, 2HIV/AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland; 3Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa
Abstract: Integrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no specific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as a fixed-dose combination. However, the drug requires boosting and this leads to a number of drug–drug interactions and necessary dose adjustment when dosing with certain drugs, including dose reduction in the presence of atazanavir, lopinavir, rifabutin, and ketoconazole, and dose increase for ethinyl estradiol when co-administered with boosted elvitegravir. The main advantage of elvitegravir lies in its potential to be administered as a once-daily, single pill. Limitations include dose adjustment requirements, a relatively low genetic barrier to resistance, high price, and lack of data for use in children. Clinical trials addressing specific challenges encountered in resources-limited settings should be encouraged.
Keywords: elvitegravir, efficacy, safety, resistance, resource-limited settings
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Nathan Ford
Readers of this article also read:
- Interested in being a peer-reviewer?
Click here to register.
"I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.
- MLA'14 -
May 16–21, 2014
- Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi
- Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome
- Treatment of drug-resistant tuberculosis
- Lyme disease: the next decade